Peter M. Irving

Guy's and St Thomas' NHS Foundation Trust — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

74h-index19.1kcitations701works10.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(407), Microscopic Colitis(220), Eosinophilic Esophagitis(72), Biosimilars and Bioanalytical Methods(65), Immunodeficiency and Autoimmune Disorders(63)

Publications691 total

Real-world effectiveness of risankizumab in Crohn’s disease: a pan UK retrospective cohort study
Frontline Gastroenterology·2026Open Access
CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource
Value in Health·2025
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
Contemporary Clinical Trials Communications·2025Open Access
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age
Inflammatory Bowel Diseases·2025Open Access
S1686 Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Extended Induction Results From the LUCENT-3 Open-Label Study
The American Journal of Gastroenterology·2025
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study
Journal of Crohn s and Colitis·2025· 1 cited
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Inflammatory Bowel Diseases·2025Open Access
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme
BMJ Open Gastroenterology·2025· 1 citedOpen Access
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease
United European Gastroenterology Journal·2025· 2 citedOpen Access
Inflammatory Bowel Disease Advice Lines: A Scoping Review.
PubMed·2025Open Access
Clinical Utility and Cost‐Effectiveness of Pretreatment <i>NUDT15</i> Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the <scp>UK NIHR</scp> Inflammatory Bowel Disease Bioresource
Alimentary Pharmacology & Therapeutics·2025· 5 citedOpen Access
O12 Emulsifier restriction is an effective therapy for active crohn’s disease: the ADDapt trial – a multi-centre, randomised, double-blind, placebo-controlled trial
Oral Presentations·2025
FP24 Ozanimod: real world outcomes from three UK centres
2025· 1 cited
P6 Real world experience of supra-escalated anti-TNF dosing in crohn’s disease
2025
O46 Inflammatory bowel disease advice lines: a scoping review
Oral Presentations·2025
Tu1858: MIRIKIZUMAB IS EQUALLY EFFECTIVE IN USTEKINUMAB-EXPOSED AND USTEKINUMAB-NAÏVE PATIENTS WITH UC: A MULTICENTRE REAL-WORLD COHORT.
Gastroenterology·2025
Su1917: SEROPROTEOMIC TESTING CAN IDENTIFY CLINICALLY WELL CROHN’S DISEASE PATIENTS WITH ACTIVE ENDOSCOPIC DISEASE
Gastroenterology·2025
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study
Digestive Diseases and Sciences·2025· 2 citedOpen Access
P0940 Patient perspectives from a real-world adalimumab biosimilar switching program
Journal of Crohn s and Colitis·2025Open Access
P0169 Relapse of ulcerative colitis on dose reduction of tofacitinib is associated with markers of T-cell activation but not clinical features: a prospective, multicentre observational study
Journal of Crohn s and Colitis·2025Open Access
page 1 of 35Next →

Frequent Co-authors

Tariq Ahmad(14), Nicholas A. Kennedy(13), Miles Parkes(13), James O. Lindsay(13), Charlie W. Lees(12), Miranda Lomer(12), Kevin Whelan(12), Ailsa Hart(11), Shaji Sebastian(10), Claire Bewshea(9), James Goodhand(9), Heidi M. Staudacher(9), Neil Chanchlani(8), Daniel R. Gaya(8), Richard K. Russell(8), Simeng Lin(7), Fraser Cummings(7), Christopher A Lamb(7), Jacqueline S. Barrett(6), Rachel Nice(6)